The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $285.87

Today's change-9.21 -3.12%
Updated September 29 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $285.87

Today's change-9.21 -3.12%
Updated September 29 4:00 PM -4GMT. Delayed by at least 15 minutes.

Ishares Nasdaq Biotechnology crosses below 50-day moving average

Ishares Nasdaq Biotechnology closed sharply lower Thursday, dropping (U.S.)$9.21 or 3.12% to (U.S.)$285.87 and crossing below its 50-day moving average. Over the last five days, shares have lost 4.74% and are down 15.51% for the last year to date. This security has underperformed the S&P 500 by 15.42% during the last year.

Key company metrics

  • Open(U.S.) $294.39
  • Previous close(U.S.) $295.08
  • High(U.S.) $295.31
  • Low(U.S.) $285.16
  • Bid / Ask(U.S.) $286.29 / (U.S.) $287.39
  • YTD % change-15.51%
  • Volume1,575,012
  • Average volume (10-day)1,350,185
  • Average volume (1-month)1,377,198
  • Average volume (3-month)1,525,584
  • 52-week range(U.S.) $240.03 to (U.S.) $343.87
  • Beta1.13
  • Trailing P/E3.15×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.44
  • Dividend yield0.15%
  • Trailing EPS(U.S.) $90.83
Updated September 29 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.16%Sector:FinancialsIndustry:Investment Trusts

Latest Company News

Latest Press Releases

    No Press Release Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q2/2015Q4/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Sep 30, 201409/30/2014Mar 31, 201403/31/2014Sep 30, 201309/30/2013
Revenue92198
Total other revenue--------
Total revenue92198
Gross profit--------
Total cost of revenue--------
Total operating expense1612118
Selling / general / administrative1612118
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-79-20
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax1,572718446878
Income after tax1,572718446878
Income tax, total0000
Net income1,572718446878
Total adjustments to net income--------
Net income before extra. items1,572718446878
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,572718446878
Inc. avail. to common incl. extra. items1,572718446878
Diluted net income1,572718446878
Dilution adjustment----0--
Diluted weighted average shares29202319
Diluted EPS excluding extraordinary itemsvalue per share54.7736.0619.0345.62
Dividends per sharevalue per share0.000.450.000.07
Diluted normalized EPSvalue per share54.7736.0619.0345.62